Stockreport

What is Bio-Path Holdings' latest development in treating obesity in Type 2 diabetes patients? [Yahoo! Finance]

FOXO Technologies Inc.  (FOXO) 
PDF The preclinical studies showed that BP1001-A reduced Grb2 protein expression in myoblast cells and increased the levels of phosphorylated AKT and phosphorylated FOXO-1 [Read more]